Skip to results
Modify your search
NARROW
1-17 of 17
Authors: Inna Smalley
Journal Article
BSLM-03 BRANCHED-CHAIN KETO ACIDS PROMOTE AN IMMUNE-SUPPRESSIVE AND NEURODEGENERATIVE MICROENVIRONMENT IN LEPTOMENINGEAL DISEASE Open Access
Neuro-Oncology Advances, Volume 6, Issue Supplement_1, August 2024, Page i5, https://doi.org/10.1093/noajnl/vdae090.014
Published: 02 August 2024
Journal Article
BSLM-02 SPATIAL TRANSCRIPTOMICS ANALYSIS IDENTIFIES A UNIQUE TUMOR-PROMOTING FUNCTION OF THE MENINGEAL STROMA IN MELANOMA LEPTOMENINGEAL DISEASE Open Access
Neuro-Oncology Advances, Volume 6, Issue Supplement_1, August 2024, Page i5, https://doi.org/10.1093/noajnl/vdae090.013
Published: 02 August 2024
Journal Article
EDITOR'S CHOICE
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions Open Access
Neuro-Oncology, Volume 26, Issue 10, October 2024, Pages 1781–1804, https://doi.org/10.1093/neuonc/noae103
Published: 21 June 2024
Journal Article
SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING Open Access
Neuro-Oncology Advances, Volume 5, Issue Supplement_3, August 2023, Page iii28, https://doi.org/10.1093/noajnl/vdad070.111
Published: 04 August 2023
Journal Article
TIPS-04 A RANDOMIZED, MULTI-INSTITUTIONAL PILOT STUDY TO EVALUATE THE MOLECULAR AND CELLULAR RESPONSE TO TREATMENT WITH NIVOLUMAB WITH EITHER ADJUVANT IPILIMUMAB OR RELATLIMAB IN ADULT PATIENTS WITH SURGICALLY RESECTABLE MELANOMA BRAIN METASTASES: ONGOING TRIAL Open Access
Neuro-Oncology Advances, Volume 5, Issue Supplement_3, August 2023, Page iii34, https://doi.org/10.1093/noajnl/vdad070.135
Published: 04 August 2023
Journal Article
CTIM-01. TITLE: PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD): PRELIMINARY RESULTS Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii59, https://doi.org/10.1093/neuonc/noac209.233
Published: 14 November 2022
Journal Article
NCMP-04. COMBINATION BRAF/MEK INHIBITION IMPROVES SURVIVAL WITH LEPTOMENINGEAL DISEASE FROM MELANOMA IN A SINGLE INSTITUTIONAL REVIEW AT MOFFITT CANCER CENTER Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii191, https://doi.org/10.1093/neuonc/noac209.732
Published: 14 November 2022
Journal Article
A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma Open Access
Neuro-Oncology, Volume 24, Issue 10, October 2022, Pages 1673–1686, https://doi.org/10.1093/neuonc/noac054
Published: 25 February 2022
Journal Article
BIOM-02. LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA: UPDATES ON THE VALIDITY OF THE VERIDEX CELLSEARCH SYSTEM Free
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi10, https://doi.org/10.1093/neuonc/noab196.034
Published: 12 November 2021
Journal Article
LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival Open Access
Neuro-Oncology Advances, Volume 3, Issue Supplement_3, August 2021, Pages iii7–iii8, https://doi.org/10.1093/noajnl/vdab071.028
Published: 09 August 2021
Journal Article
LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results Open Access
Neuro-Oncology Advances, Volume 3, Issue Supplement_3, August 2021, Page iii8, https://doi.org/10.1093/noajnl/vdab071.030
Published: 09 August 2021
Journal Article
LMD-07. In Vitro AND In Vivo Culture of Patient Derived-Cerebral Spinal Fluid-Circulating Tumor Cells (PD-CSF-CTCs) in Leptomeningeal Disease (LMD) From Melanoma to Identify Novel Treatment Strategies Open Access
Neuro-Oncology Advances, Volume 3, Issue Supplement_3, August 2021, Page iii8, https://doi.org/10.1093/noajnl/vdab071.032
Published: 09 August 2021
Journal Article
OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases Open Access
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii17, https://doi.org/10.1093/noajnl/vdab070.068
Published: 05 July 2021
Journal Article
TMOD-02. IN VITRO & IN VIVO CULTURE OF PATIENT DERIVED (PD) CSF-CTCS IN LEPTOMENINGEAL DISEASE (LMD) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii227–ii228, https://doi.org/10.1093/neuonc/noaa215.953
Published: 09 November 2020
Journal Article
CMET-26. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCS IN LEPTOMENINGEAL DISEASE (LMDZ) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi57, https://doi.org/10.1093/neuonc/noz175.227
Published: 11 November 2019
Journal Article
LPTO-03. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES Open Access
Neuro-Oncology Advances, Volume 1, Issue Supplement_1, August 2019, Pages i6–i7, https://doi.org/10.1093/noajnl/vdz014.026
Published: 12 August 2019
Journal Article
EXTH-39. DETECTION, MOLECULAR PROFILING AND CULTURE OF CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) IN MELANOMA TO IMPROVE DIAGNOSIS AND TREATMENT STRATEGIES Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi93, https://doi.org/10.1093/neuonc/noy148.387
Published: 05 November 2018
